Thomas Steve Deisboeck, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Biological | 36 | 2018 | 9469 | 2.500 |
Why?
|
| Neoplasm Invasiveness | 14 | 2007 | 3597 | 1.210 |
Why?
|
| Neoplasms | 27 | 2023 | 22173 | 1.100 |
Why?
|
| Systems Biology | 7 | 2014 | 481 | 1.080 |
Why?
|
| Brain Neoplasms | 21 | 2009 | 9031 | 0.940 |
Why?
|
| Computer Simulation | 17 | 2014 | 6241 | 0.790 |
Why?
|
| Cell Movement | 12 | 2009 | 5205 | 0.760 |
Why?
|
| Spheroids, Cellular | 8 | 2008 | 330 | 0.750 |
Why?
|
| Thermodynamics | 4 | 2023 | 595 | 0.720 |
Why?
|
| Glioma | 8 | 2008 | 3455 | 0.480 |
Why?
|
| Models, Theoretical | 4 | 2015 | 3575 | 0.470 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 4915 | 0.460 |
Why?
|
| Ion Channels | 1 | 2018 | 1040 | 0.430 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2014 | 195 | 0.420 |
Why?
|
| Cell Proliferation | 11 | 2023 | 10448 | 0.420 |
Why?
|
| Cell Division | 11 | 2008 | 4465 | 0.400 |
Why?
|
| Database Management Systems | 1 | 2012 | 257 | 0.380 |
Why?
|
| Epidermal Growth Factor | 3 | 2009 | 702 | 0.370 |
Why?
|
| Glioblastoma | 6 | 2009 | 3482 | 0.370 |
Why?
|
| Computational Biology | 6 | 2012 | 3517 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 8 | 2008 | 6132 | 0.370 |
Why?
|
| Models, Genetic | 3 | 2005 | 3442 | 0.350 |
Why?
|
| Cell Membrane | 2 | 2018 | 3687 | 0.340 |
Why?
|
| Models, Statistical | 5 | 2020 | 5079 | 0.340 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 302 | 0.330 |
Why?
|
| Biophysics | 2 | 2007 | 380 | 0.320 |
Why?
|
| Internet | 3 | 2012 | 3093 | 0.320 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3617 | 0.310 |
Why?
|
| Chemotaxis | 3 | 2006 | 598 | 0.300 |
Why?
|
| Biological Science Disciplines | 1 | 2008 | 57 | 0.300 |
Why?
|
| Algorithms | 14 | 2020 | 14032 | 0.280 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 13642 | 0.280 |
Why?
|
| Computer-Aided Design | 1 | 2008 | 300 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 5315 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 5 | 2011 | 2644 | 0.270 |
Why?
|
| Game Theory | 1 | 2005 | 23 | 0.250 |
Why?
|
| Fractals | 1 | 2006 | 127 | 0.250 |
Why?
|
| Cell Count | 2 | 2006 | 1835 | 0.240 |
Why?
|
| Collagen Type I | 1 | 2008 | 616 | 0.230 |
Why?
|
| Paracrine Communication | 1 | 2005 | 277 | 0.230 |
Why?
|
| Disease Progression | 8 | 2011 | 13510 | 0.220 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 1258 | 0.220 |
Why?
|
| Callithrix | 1 | 2003 | 94 | 0.220 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2003 | 65 | 0.210 |
Why?
|
| Lung Neoplasms | 5 | 2014 | 13382 | 0.210 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 1486 | 0.190 |
Why?
|
| Signal Transduction | 6 | 2014 | 23447 | 0.190 |
Why?
|
| Models, Neurological | 1 | 2009 | 1769 | 0.190 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1505 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 3 | 2008 | 1349 | 0.170 |
Why?
|
| Gels | 3 | 2008 | 420 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2010 | 4063 | 0.170 |
Why?
|
| Herpesvirus 1, Human | 1 | 2003 | 753 | 0.150 |
Why?
|
| Humans | 48 | 2023 | 761572 | 0.140 |
Why?
|
| Ion Transport | 1 | 2018 | 319 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2008 | 2321 | 0.130 |
Why?
|
| Cell Death | 2 | 2016 | 1679 | 0.120 |
Why?
|
| User-Computer Interface | 2 | 2012 | 1400 | 0.120 |
Why?
|
| Genetic Vectors | 2 | 2003 | 3396 | 0.120 |
Why?
|
| Animals | 15 | 2018 | 168467 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2009 | 36429 | 0.110 |
Why?
|
| Research Design | 1 | 2008 | 6180 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8002 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2004 | 2791 | 0.100 |
Why?
|
| Semantics | 2 | 2012 | 613 | 0.100 |
Why?
|
| Biological Transport | 1 | 2016 | 2091 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 5336 | 0.090 |
Why?
|
| Computer Graphics | 1 | 2012 | 340 | 0.090 |
Why?
|
| Mitosis | 1 | 2016 | 1188 | 0.090 |
Why?
|
| Mathematical Concepts | 1 | 2010 | 73 | 0.090 |
Why?
|
| Kinetics | 2 | 2009 | 6374 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 1989 | 0.080 |
Why?
|
| raf Kinases | 1 | 2009 | 118 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2004 | 6635 | 0.080 |
Why?
|
| Drug Design | 1 | 2013 | 1048 | 0.080 |
Why?
|
| Phenotype | 4 | 2006 | 16592 | 0.070 |
Why?
|
| Surface Tension | 1 | 2007 | 43 | 0.070 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2007 | 90 | 0.070 |
Why?
|
| Cell Communication | 2 | 2005 | 1657 | 0.070 |
Why?
|
| Apoptosis | 2 | 2018 | 9489 | 0.070 |
Why?
|
| Diffusion | 1 | 2008 | 814 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2009 | 476 | 0.070 |
Why?
|
| Viscera | 1 | 2006 | 138 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 670 | 0.070 |
Why?
|
| GTPase-Activating Proteins | 1 | 2009 | 471 | 0.060 |
Why?
|
| Mathematics | 1 | 2007 | 707 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2013 | 1051 | 0.060 |
Why?
|
| Bystander Effect | 1 | 2005 | 90 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 615 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2003 | 18253 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 823 | 0.060 |
Why?
|
| Phospholipase C gamma | 1 | 2004 | 131 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 675 | 0.060 |
Why?
|
| Type C Phospholipases | 1 | 2004 | 287 | 0.060 |
Why?
|
| Acceleration | 1 | 2005 | 189 | 0.060 |
Why?
|
| Neuropil | 1 | 2003 | 31 | 0.060 |
Why?
|
| ras Proteins | 1 | 2009 | 1054 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2009 | 1893 | 0.060 |
Why?
|
| Time Factors | 5 | 2009 | 39970 | 0.050 |
Why?
|
| Orientation | 1 | 2005 | 321 | 0.050 |
Why?
|
| Probability | 1 | 2008 | 2477 | 0.050 |
Why?
|
| RNA Viruses | 1 | 2004 | 111 | 0.050 |
Why?
|
| Astrocytoma | 1 | 2007 | 775 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2008 | 819 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 9280 | 0.050 |
Why?
|
| Cell Aggregation | 1 | 2002 | 239 | 0.050 |
Why?
|
| Mathematical Computing | 1 | 2002 | 142 | 0.050 |
Why?
|
| Biophysical Phenomena | 1 | 2002 | 320 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2811 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2023 | 265 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1962 | 0.050 |
Why?
|
| Models, Structural | 1 | 2001 | 340 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2005 | 11121 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2007 | 1499 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8656 | 0.040 |
Why?
|
| Adaptation, Biological | 1 | 2001 | 147 | 0.040 |
Why?
|
| Prostate | 1 | 2008 | 1773 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2007 | 3088 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2007 | 8552 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2012 | 7967 | 0.040 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 286 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2023 | 1090 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2000 | 252 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2005 | 1726 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 1674 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2006 | 2932 | 0.040 |
Why?
|
| Software | 2 | 2012 | 4434 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2009 | 8321 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2010 | 3877 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2008 | 2882 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2002 | 1869 | 0.040 |
Why?
|
| Collagen | 1 | 2005 | 2638 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1787 | 0.030 |
Why?
|
| Mutation | 3 | 2008 | 30054 | 0.030 |
Why?
|
| Necrosis | 1 | 2000 | 1611 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 2915 | 0.030 |
Why?
|
| Public Health | 1 | 2009 | 2669 | 0.030 |
Why?
|
| Viruses | 1 | 1999 | 375 | 0.030 |
Why?
|
| Brain | 3 | 2009 | 27120 | 0.030 |
Why?
|
| Linear Models | 1 | 2005 | 5872 | 0.030 |
Why?
|
| Contrast Media | 1 | 2008 | 5311 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 1998 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6075 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 3359 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4352 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15266 | 0.030 |
Why?
|
| Glucose | 1 | 2004 | 4346 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14666 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2008 | 3429 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 64684 | 0.020 |
Why?
|
| Survival Rate | 2 | 2003 | 12725 | 0.020 |
Why?
|
| Aged | 4 | 2009 | 169310 | 0.020 |
Why?
|
| Programming Languages | 1 | 2012 | 128 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 16986 | 0.020 |
Why?
|
| Genotype | 1 | 2005 | 12990 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2023 | 4513 | 0.020 |
Why?
|
| Systems Integration | 1 | 2012 | 426 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 39107 | 0.020 |
Why?
|
| Male | 6 | 2009 | 360842 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 29629 | 0.020 |
Why?
|
| Neoplastic Processes | 1 | 2008 | 35 | 0.020 |
Why?
|
| Kidney | 1 | 2003 | 7047 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7529 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2000 | 3060 | 0.020 |
Why?
|
| Microscopy | 1 | 2012 | 903 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 6346 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 11122 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2005 | 110 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 9002 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 9177 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 3422 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2008 | 709 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2005 | 490 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 81533 | 0.010 |
Why?
|
| Rats, Nude | 1 | 1999 | 105 | 0.010 |
Why?
|
| Brain Abscess | 1 | 2000 | 120 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 280 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 1971 | 0.010 |
Why?
|
| Light | 1 | 2005 | 1353 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1999 | 826 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2000 | 555 | 0.010 |
Why?
|
| Retroviridae | 1 | 2000 | 850 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 5791 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2000 | 903 | 0.010 |
Why?
|
| Female | 4 | 2004 | 392686 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1999 | 735 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 2016 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1999 | 1395 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1999 | 1526 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 2397 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1999 | 2220 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 10766 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 2612 | 0.010 |
Why?
|
| Adult | 2 | 2004 | 221203 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 5247 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1999 | 3156 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1999 | 3066 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11076 | 0.000 |
Why?
|
| United States | 1 | 2012 | 72335 | 0.000 |
Why?
|
| Rats | 1 | 1999 | 23741 | 0.000 |
Why?
|
| Middle Aged | 1 | 2000 | 220920 | 0.000 |
Why?
|